Last reviewed · How we verify
Entecavir+Carvedilol
This combination uses entecavir to inhibit hepatitis B virus reverse transcriptase and carvedilol to block beta-adrenergic receptors, addressing both viral replication and portal hypertension complications.
This combination uses entecavir to inhibit hepatitis B virus reverse transcriptase and carvedilol to block beta-adrenergic receptors, addressing both viral replication and portal hypertension complications. Used for Chronic hepatitis B with advanced fibrosis or cirrhosis, Hepatitis B-related portal hypertension with variceal bleeding risk.
At a glance
| Generic name | Entecavir+Carvedilol |
|---|---|
| Sponsor | ShuGuang Hospital |
| Drug class | Antiviral + Beta-blocker combination |
| Target | HBV reverse transcriptase; beta-1, beta-2, and alpha-1 adrenergic receptors |
| Modality | Small molecule |
| Therapeutic area | Hepatology / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Entecavir is a nucleoside reverse transcriptase inhibitor that suppresses HBV replication by blocking viral polymerase activity. Carvedilol is a non-selective beta-blocker with alpha-blocking properties that reduces portal pressure and decreases variceal bleeding risk in patients with advanced liver disease. The combination targets both the underlying viral infection and hemodynamic complications of cirrhosis.
Approved indications
- Chronic hepatitis B with advanced fibrosis or cirrhosis
- Hepatitis B-related portal hypertension with variceal bleeding risk
Common side effects
- Lactic acidosis
- Fatigue
- Dizziness
- Bradycardia
- Hepatic decompensation
Key clinical trials
- Carvedilol for Prevention of Esophageal Varices Progression (NA)
- Extension Study of Carvedilol RCT Study (NA)
- Treatment of Moderate and Severe Cirrhotic Portal Hypertension Due to HBV With Fuzheng Huayu and Entecavir (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Entecavir+Carvedilol CI brief — competitive landscape report
- Entecavir+Carvedilol updates RSS · CI watch RSS
- ShuGuang Hospital portfolio CI